4/21/2015
`
`Management 1 Vital Therapies
`
`ABOUT US I BOARD OF DIRECTORS I MANAGEMENT
`
`Management
`Teny 1-Wnte~W, Ph.D., Co-Chairman and Chief Executive Officer
`Dr. \Ninters has served as the Chairman of our board of directors from June 2003 to
`March 2013. Dr. IMnters became Co-Chairman of our board of dlrectors in March
`2013 and currently serves as such. Dr. \Mnters has served as our Chief Executive
`Officer since June 2003. Dr. \Mnters is also a Special Umited Partner of Valley
`Ventures, an investor-in Vital Therapies since May 2003. He was forme~y a General
`Partner of Columbine Venture Funds and VIce President of DS Ventures, a venture
`capital subsldlmy of Diamond Shamrock Corp., a chemical, life science and
`petroleum company. Dr. IMnters was previously a director of three public companies:
`CollaGenex Pharmaceuticals, Inc., a developer and marketer of proprietary medical
`thareples to the dermatology market, Orthologlc Corp., a biotechnology company
`focused on development and commercialization of novel synthetic peplides for tissue
`repair and healing, and Cllnuvel Pharmaceuticals, a global blopharmaceutlcal
`company committed to developing drugs for the trealment of a range of severe skin
`dfsorders. Or. \Ninlers has also served as a director of over 20 private companies. He
`earned a B.Sc. as well as a Ph.D. In chemistry from the University of Wales, U.K. He
`also completed a post-doctoral fellowship at the University of California, Los Angeles.
`
`Jiii'Pitt'ji(~.~~l~iiiM!ili{!\®l~fifrtml!J!'!!!U!li!!~P· Executive VIce President
`Mr. Ashley has served as our Executive Vice President and Chief Technical Officer
`since September 2013. Between May 2008 and September 2013, he served as our
`VIce President and Chief Opereling Officer. Mr. Ashley's career in the
`pharmaceutical industry extends for 34 years. He was form~y Chairman, President
`and Chief Executive Officer of AmpiiMed C01p0ratlon, a privately-held cancer drug
`development company from January 2004 to March 2007, and Senior Vice President
`of Commercial Development at CollaGenex Pharmaceuticals, Inc., a publicly-held
`pharmaceutical company, from September 1994 to December 2003. Prior to that he
`held positions of Increasing responsibility at Bristol-Myers Squibb from Janumy 1989
`to September 1994, and With Amersham lntema~.on~!Jrptn 1979 to 1989. Re1U$.!!4;!1!,
`M~~~~~~,~~!~<f.I!!!Pblimisey;fiOfi\'\Oiifarif'ti~Wiiili'ft~'liMr. Ashley Is the Inventor-~!'
`several issued and pending patents, as well as the author of several scientific
`papers. He serves on the Board of Directors of R01141ar Pharmaceuticals, a privately-
`held manufacturer of proprietary dental pharmaceuticals.
`
`Duane Nash, M.D., J.D., M.B.A., Chief Business Offlcer, Executive VIce
`President
`Dr. Nash has served as our Executive Vice President since May 2013 and as our
`Chief Business Officer since March 2012. Between March 2012 and May 2013, he
`also served as our Medical Director. Dr. Nash completed his Internship In general
`surgery at the University of California at San Francisco durtng which he served as a
`member of the liver transplant team. Dr. Nash also practiced as an attorney from
`November 2002 to February 2008, most recently at the law firm of Davis Polk, where
`he focused on Intellectual property Rtlgation and corporate matters. Dr. Nash joined
`Vital Therapies from Wedbush PacGrow Ufe Sciences where he was employed from
`March 2009 to March 2012 serving most recently as Vice President in Equity
`Research. Before that he was a research analyst at Pacific Growth Equities from
`April 2008 through March 2009, which was subsequently acquired by Wedbush
`Securities, Inc. Dr. Nash has served on the board of directors of Akebla
`Therapeutics, Inc., a publicly-traded biotech company focused on the treatment of
`anemia and vascular disease since May 2013, and on the board of directors of Aerplo
`Therapeutics Inc., a clinical-stage blopharmaceutical company focused on advancing
`lmovatrve therapies for vascular dlseases, since September 2012. Dr. Nash earned a
`B.A. In biology from \Mlliams College, an M.D. from Dartmouth Medical School, a
`J.D. from the University of Callfomla, Berkeley, and an M.B.A. from the University of
`Oxford.
`
`Michael V. Swanson, M.B.A., Chief Financial Officer
`Mr. Swanson joined us In August 2013 as our Chief Financial Officer. Mr. Swanson
`has over 20 years of experience In senior financial positions In both public and
`private life sciences companies. Mr. Swanson was Chief Financial Officer of Amlra
`Pharmaceuticals, Inc., a pharmaceutical company focused on the discovery and
`ea~y development of drugs to treat lnflammaJory and fibrotic diseases, from May
`2008 until the company was acquired In September 2011, and of Panmira
`Pharmaceuticals, LLC, a spin out from Amira from September to December 2011.
`Since January 2012, Mr. Swanson has been provldlng financial consulting services to
`development stage companies. From July 2000 to April 2008, Mr. Swanson served In
`senior finance positions lncludlng Senior Vice President, Finance and Chief Financial
`
`http:/Mtaltheraples.com/corporatelmanagemern/
`
`CONTACT
`CAREERS
`
`News
`Vital Therapies Announces Fourth Quarter and Full
`Year 2014 Financial Results and Provides a
`Coroorate Update
`
`Y!.t<!L'l:lmlllllll!.~ Aooru.m_q@§..f.Q.I!.ItJ.tQ!!.~r.2.ild£.vll
`Y..ar..?.Q.H..Elrt~Res.!.!ll!i Conf~!l.LCJ!ILYl.!!!l
`~
`'llll.!ll.Ib!lr~Q.~nces VT!-208 Phase 3 Clinical
`I!:!m.B!!aches Enrollment Taro111
`l MORE NEWS AND EVENTS I
`
`VITAL THERAPIES FACT SHEET
`
`VITAL THERAPIES, INC
`15010 Avenue of Science
`Suite200
`San Diego, CA 92128
`TEL (858) 67~ I FAX (858) 67~843
`CONTACT FOR GENERAL INFORMATION
`
`Dr. Reddy's Laboratories, Ltd., et al.
`v.
`Galderma Laboratories, Inc.
`IPR2015-__
`Exhibit 1052
`
`1/3
`
`Exh. 1052
`
`

`
`4/21/2015
`
`Management 1 Vital Therapies
`Officer at Prometheus Labaratones lnc., a specialty pharmaceutical company
`marketing and selling pharmaceutical products and diagnostic testing services for
`gasireintestinal diseases and disorders. Previously, Mr. Swanson was Senior Vice
`President and Chief Financial Officer of Advanced Tissue Sciences, lnc., a publicly-
`traded biomedical company, where he served in senior financial positions for over ten
`years. Mr. Swanson also served as Director of Finance of the Fisher Seienlilie
`Group, lnc., a health and scientific technology company, and its parent, The Henley
`Group, lnc., a widely diversified holding company. Mr. Swanson began his career
`working approximately nine years with the public accounting firm of Deloitte Haskins
`& Seils, now Deloitte & Tauche LLP. Mr. Swanson eamed a B.S. in business
`administration from the Califomia Polylechnie State University at San Luis Obispo
`and an M.B.A. from the University of Southem Califomia. He is also a Certified
`Public Accountant (inactive).
`
`John Dunn, General Counsel
`Mr. Dunn joined us in November 2014 as our General Counsel. Mr. Dunn has over 25
`years of nationallaw firm and in-hause general counsel experience. Mr. Dunn was
`Senior Vice President Legal and Compliance, General Counsel and Secretary of
`IDEC Pharmaceuticals from 2002 until its mergerwith Biogen in late 2003. From
`2004 to 2012, Mr. Dunn served as an Executive Vice President at Biogen Idee where
`he was in charge of Biogen ldec's intemal cerparate venture fund and Innovation
`lncubator. Most recently, Mr. Dunn has been providing legal and cerparate
`development advisory services to ernerging life science companies. Previously, Mr.
`Dunn was a partner for 16 years in the Corporate, Securities and Technology Group
`at the Pillsbury Winthrop law firm where his practice focused on the healthcare
`industry. Mr. Dunn eamed a B.S. in finance and his J.D. from the University of
`\11/yoming. He serves as an advisor to TVM Capital, a life science venture capital firm
`and is a member of the Board of Directors of Agility-Ciinical, a privately held
`consulting and contract research organization.
`
`Andrew Henry, Vice ?resident of Clinical Operations
`Mr. Henry hasservedas ourVice President of Clinical Operations since April2013.
`Mr. Henry is responsible for the global implementation of our clinical program. Mr.
`Henry has 25 years of experience managing clinical trials in life science companies
`with roles at Schering-Piough Oncology, Novartis Oncology and Medlmmune.
`Between January 2009 and February 2013, Mr. Henry served as Senior Director of
`Clinical Trial Management and Senior Director of Global Clinical Operational Strategy
`at Medlmmune, a biophannaceutical company that is under AstraZeneca's biologics
`division. At Medlmmune, Mr. Henry oversaw operations of all clinical studies being
`performed by the company across all therapeutic areas. From November 1997 to
`August 2008, Mr. Henry held roles as Senior Clinical Research Seienlist and Head
`Clinical Resources and Development Director at Novartis Oncology, an ethical
`pharmaceutical company, where he oversaw clinical studies and the Department of
`Clinical Research Scientists/Ciinical Trial Heads. Mr Henry eamed a B.S. in biology
`and biopsychology from William Patersan University.
`
`Andrea Loewen, Vice President of Regulatory Affairs and Quality
`Ms. Leewen has served as our Vice President of Regulatory Affairs and Quality since
`July 2013 and oversees our quality and regulatory systems and develops regulatory
`strategies. Ms. Leewen has 24 years of experience in regulatory and quality
`management roles, including positions at Baxter Healthcare, Biogen Idee, and Shire
`Pharmaceuticals. From June 2009 to July 2013, she served as the Head of
`Regulatory Affairs for Shire Pharmaceuticals Regenerative Medicine business unit,
`where she was responsible for global regulatory strategy and filings for development
`stage and commercial combination products. Between March 2008 and June 2009,
`Ms. Leewen served as Senior Director of Regulatory Affairs for Ceregene, lnc., a
`development stage biotech company, and was responsible for global regulatory
`strategy and filings for combination products. Ms. Leewen eamed her B.A. in biology
`from Gustavus Adolphus College.
`
`Richard Murawski, Vice ?resident of Manufacturing
`Mr. Murawski hasservedas ourVice President of Manufactunng since July 2013.
`Mr. Murawski has more than 40 years of experience in manufacturing facility design,
`construction, start-up, validation, and supply chain management, both domestically
`and intemationally, including 17 majorplant start-ups. From February 2013 to July
`2013, Mr. Murawski was self-employed as a consultant. From June 2010 to February
`2013, Mr. Murawski served as the Vice President/General Manager for Dendreon
`Corporation, a biotech manufactunng company, with responsibility for, among others,
`manufactunng, engineering, malenals management, and facilities. Between June
`2008 and July 2010, Mr. Murawski served as Chief Executive Offleer of Murawski
`and Associates, a biotech consulting company, where he consulted companies an
`managing operations and biopharmaceutical facilities. From June 2002 to July 2008,
`Mr. Murawski served as Senior Vice President of Operations and Gorparate Officer of
`Favrille, lnc., a biotech manufactunng company, and was responsible for
`manufactunng, engineering, malenals management, facilities, technical services, and
`EHS functions. Mr. Murawski eamed his B.S. in Chemical Engineering from the
`Newark College of Engineering at the New Jersey Institute of Technology.
`
`Aron P. Stern, M.B.A., Chief Administration Offleer
`Mr. Stern hasservedas our Chief Administrative Officer since August 2013 and as
`our Secretary since October 2005. Between June 2003 and August 2013, Mr. Stern
`served as our Treasurer, Vice President and Chief Financial Officer. Mr. Stern has
`
`http://vitaltherapies.com/corporate/managemenV
`
`213
`
`Exh. 1052
`
`

`
`4/21/7.015
`
`Management 1 Vital Therapies
`over 20 years of experteneo in capital formation, acquisitions, financial strategy and
`financial and operalienal management in growth-stage high technology and
`biotechnology companies. He previously was Chief Financial Offleer at each of
`Protein Polymer Technologies, lnc., a developer of a protein-based technology, 4-D
`Neuroimaging, a medical equipment manufacturtng company, and VitaGen, lnc., our
`predecessor company. Mr. Stern also held positions at Apple Computer and lsis
`Pharmaceuticals, a developer of antisense drugs. Mr. Stern eamed a B.S. in
`economics and business administration and an M.B.A. in finance and markeling from
`the University of Califomia, Berkeley.
`
`Albert Kildani, Vice President, Investor Relations and Business Development
`Mr. Kildani joined us in September 2014 as our Vice President, Investor Relations
`and Business Development. From August 2012 to August 2014, Mr. Kildani was
`Senior Director, Investor Relations for Hologic, lnc., a global medical device
`company, following its acquisilion of Gen-Probe lncorporated in 2012, where he
`served in the same role. Prior to entertng the life sciences industry, Mr. Kildani spent
`over 12 years on Wall Street in Investment banking, analyst and portfolio
`management roles, all with a focus on healthcare. From 2010 to 2011, Mr. Kildani
`was Managing Director at Global Hunter Securtties where he led the healthcare
`Investment banking effort. From 2004 to 2009, Mr. Kildani was a Director with SF
`Capital, a uni! of Stark Investments, where he focused on Investments in
`biotechnology, and medical device companies. Previously, Mr. Kildani spent seven
`years as a sell-side analyst with C.E. Unterberg, Towbin and Pacific Growth Equities
`covering a variety of industries within healthcare including biotechnology, medical
`devices, diagnostics, life science tools and specialty services. Mr. Kildani has a
`Bachelor of Science in Finance from Boston College.
`
`Vita!Thet·aples, lncorporatad 1 TEL(858) 673-6840 1 FAX (858) 673-6843 I 15010 Avenue ofScience Suite 200 I San Diego, CA 92128
`The ELAO System has not been demonstrated tobe safe or effective for any indication and is not available for sale in the United States or any other
`country. CAUTION: lnvestigational New Drug. Limited by Federal (or United States) law to investigational use.
`Copyright@ 2008-2015 Vital Therapies, lnc. All rights reserved
`
`SITEMAP I GONTACTUS I CAREERS I PRIVACYPOLICY I
`
`http://vitaltherapies.com/corporate/management/
`
`313
`
`Exh. 1052